This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Sign In   |   Register
News: EAS Academy

New on EAS ACADEMY - Introducing Themed SHORT TRACKS

Thursday 26 April 2018   (0 Comments)
Share |

In SHORT TRACKS we collect 2-4 recent lectures from EAS congresses or courses, putting them together to provide up-to-date perspectives on a given current topic.

This month’s SHORT TRACK topic is Triglyceride-rich Lipoproteins and their Remnants in Cardiovascular Disease. Under this headline we have gathered the three presentations described below.

To the SHORT TRACK Triglyceride-rich Lipoproteins and their Remnants in Cardiovascular Disease >> 

These presentations are open for EAS members only. Register as an EAS Individual member, and the whole ACADEMY is open for you.

How to register as an EAS member >>

SHORT TRACK :: Triglyceride-rich Lipoproteins and their Remnants in Cardiovascular Disease

Demystifying the management of hypertriglyceridemia

A presentation by Professor Anne Tybjaerg-Hansen from Copenhagen University Hospital and Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. In this presentation we get basics on triglycerides and CVD risk and are also taken through the underlying genetic studies, primarily based on the data from Copenhagen. Furthermore Professor Tybjaerg-Hansen tells us about the new treatment targets that are being developed based on Mendelian randomization studies.

To the presentation >>

Why TG-Rich Lipoproteins/non-HDL cholesterol matter when assessing CVD RISK? – Atherogenic dyslipidaemia

This presentation is made by Professor Alberto Zambon, University of Padua, Italy. Professor Zambon approaches the subject from a practical point of view. What should we measure to capture the CVD risk beyond LDL and how can we interpret the analyses of different lipoprotein fraction in practice.

To the presentation >>

How to treat diabetic dyslipidaemia

Professor Gerald F Watts from Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital, School of Medicine, University of Western Australia, Australia talks about how to treat the residual risk in diabetic patients. His approach is practical and patient oriented and should be of major interest for all physicians seeing this group of patients.

To the presentation >>

Membership Software Powered by YourMembership  ::  Legal